Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III nsclc after primary chemoradiotherapy: Preliminary results from a phase I/II study

Japanese Journal of Clinical Oncology

Volumn 41, Issue 5, 2011, Pages 718-722

  Ohyanagi, Fumiyoshi ^a   Horai, Takeshi ^a   Sekine, Ikuo ^b   Yamamoto, Nobuyuki ^c   Nakagawa, Kazuhiko ^d   Nishio, Makoto ^a   Senger, Stefanie ^e   Morsli, Nassim ^e   Tamura, Tomohide ^b  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d KINDAI UNIVERSITY HOSPITAL   (Japan)

^e MERCK KGAA   (Germany)

Author keywords

Chemo respiratory tract; Immunotherapy; Lung medicine

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; BLP 25; CANCER VACCINE; CYCLOPHOSPHAMIDE; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ATRIOVENTRICULAR BLOCK; BACKACHE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSGEUSIA; FEMALE; HUMAN; HYPERURICEMIA; INJECTION SITE HEMATOMA; INJECTION SITE REACTION; INSOMNIA; JAPANESE; JOINT EFFUSION; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ARTHRALGIA; ASIAN CONTINENTAL ANCESTRY GROUP; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 79955862560     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr021     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Toyoda Y, Nakayama T, Ioka A, Tsukuma H. Trends in lung cancer incidence by histological type in Osaka, Japan. Jpn J Clin Oncol 2008;38:534-9.
3. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl. 4):68-70.
4. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, et al. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006;4:548-82.
5. Okamoto I. Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. Int J Clin Oncol 2008;13:112-6.
6. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
7. Giarelli E. Cancer vaccines: a new frontier in prevention and treatment. Oncology (Williston Park) 2007;21:11-7.
8. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51.
9. Zotter S, Hageman PC, Lossnitzer A, van den Tweel J, Hilkens J, Mooi WJ, et al. Monoclonal antibodies to epithelial sialomucins recognize epitopes at different cellular sites in adenolymphomas of the parotid gland. Int J Cancer Suppl 1988;3:38-44.
10. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int Immunol 1998;10:1907-16.
11. Guan HH, Budzynski W, Koganty RR, Krantz MJ, Reddish MA, Rogers JA, et al. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 1998;9:451-8.
12. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-81.
13. Butts C, Maksymiuk A, Goss G, Soulieres D, Marshall E, Cormier Y, et al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis. J Thorac Oncol 2007;2:S332; abstract B1_01.
14. Butts C, Anderson H, Maksymiuk A, Vergidis D, Soulieres D, Cormier Y, et al. Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(15 Suppl):3055.
15. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996;19:309-16.
16. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996;19:59-68.
17. Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001;3:49-57.
18. Study of EMD531444 in Subjects with Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy. Tokyo, Japan: Merck Serono Co. Ltd. http://clinicaltrials.gov/ct2/show/NCT00960115.